Literature DB >> 16098345

Contrast agents for MR imaging of the liver.

N Cem Balci1, Richard C Semelka.   

Abstract

Imaging of the liver is performed most often to detect and characterize focal liver lesions. MR imaging has been the method of choice to assess focal liver lesions accurately. Nonspecific intravenous contrast agents have been used for routine abdominal MR imaging protocols including liver imaging. Over the last 10 to 15 years new contrast agents have been developed that combine the excellent contrast resolution of MR imaging with improved tissue specificity. This article reviews various contrast agents that are in clinical use for liver MR imaging and discusses their potential clinical role.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098345     DOI: 10.1016/j.rcl.2005.05.004

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  12 in total

Review 1.  Advances in functional and molecular MRI technologies in chronic liver diseases.

Authors:  Iris Y Zhou; Onofrio A Catalano; Peter Caravan
Journal:  J Hepatol       Date:  2020-06-22       Impact factor: 25.083

2.  Diagnostic value of Gd-EOB-DTPA-enhanced MR cholangiography in non-invasive detection of postoperative bile leakage.

Authors:  Melahat Kul; Ayşe Erden; Ebru Düşünceli Atman
Journal:  Br J Radiol       Date:  2017-02-09       Impact factor: 3.039

Review 3.  Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy.

Authors:  Xiaoxia Cai; Qingxia Zhu; Yun Zeng; Qi Zeng; Xueli Chen; Yonghua Zhan
Journal:  Int J Nanomedicine       Date:  2019-10-21

4.  Respiratory motion in children and young adults undergoing liver magnetic resonance imaging with intravenous gadoxetate disodium contrast material.

Authors:  Leah A Gilligan; Andrew T Trout; Christopher G Anton; Andrew H Schapiro; Alexander J Towbin; Jonathan R Dillman
Journal:  Pediatr Radiol       Date:  2019-06-16

5.  Kidney function: glomerular filtration rate measurement with MR renography in patients with cirrhosis.

Authors:  Pierre-Hugues Vivier; Pippa Storey; Henry Rusinek; Jeff L Zhang; Akira Yamamoto; Kristopher Tantillo; Umer Khan; Ruth P Lim; James S Babb; Devon John; Lewis W Teperman; Hersh Chandarana; Kent Friedman; Judith A Benstein; Edward Y Skolnik; Vivian S Lee
Journal:  Radiology       Date:  2011-03-08       Impact factor: 11.105

6.  Hepatocellular carcinoma 20 mm or smaller in cirrhosis patients: early magnetic resonance enhancement by gadoxetic acid compared with gadopentetate dimeglumine.

Authors:  Cai-Zhong Chen; Sheng-Xiang Rao; Ying Ding; Shu-Jie Zhang; Feng Li; Qiang Gao; Meng-Su Zeng
Journal:  Hepatol Int       Date:  2013-08-17       Impact factor: 6.047

7.  Liver specific magnetic resonance imaging contrast medium for evaluation of focal liver lesions - Initial experience at a service hospital.

Authors:  R A George; S C Godara; V Srinivas
Journal:  Med J Armed Forces India       Date:  2012-08-20

8.  Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T.

Authors:  Cecilia Besa; Suguru Kakite; Nancy Cooper; Marcelo Facciuto; Bachir Taouli
Journal:  Acta Radiol Open       Date:  2015-01-19

9.  ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.

Authors:  E Neri; M A Bali; A Ba-Ssalamah; P Boraschi; G Brancatelli; F Caseiro Alves; L Grazioli; T Helmberger; J M Lee; R Manfredi; L Martì-Bonmatì; C Matos; E M Merkle; B Op De Beeck; W Schima; S Skehan; V Vilgrain; C Zech; C Bartolozzi
Journal:  Eur Radiol       Date:  2015-07-21       Impact factor: 5.315

10.  Non-invasive detection of biliary leaks using Gd-EOB-DTPA-enhanced MR cholangiography: comparison with T2-weighted MR cholangiography.

Authors:  Mecit Kantarcı; Berhan Pirimoglu; Nevzat Karabulut; Ummugulsum Bayraktutan; Hayri Ogul; Gurkan Ozturk; Bulent Aydinli; Yesim Kizrak; Suat Eren; Sinan Yilmaz
Journal:  Eur Radiol       Date:  2013-05-22       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.